Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

List of androgen esters

From Wikipedia, the free encyclopedia
(Redirected from Testosterone ester)

Testosterone, the base androgen of most androgen esters.

This is a list of androgen esters, including esters (as well as ethers) of natural androgens like testosterone and dihydrotestosterone (DHT) and synthetic anabolic–androgenic steroids (AAS) like nandrolone (19-nortestosterone).

Esters of natural AAS

[edit]

Testosterone esters

[edit]

Marketed

[edit]

Many esters of testosterone have been marketed, including the following major esters:[1][2]

And the following less commonly used esters:[1][2]

Never marketed

[edit]

The following major testosterone ester has not been marketed:[1][2]

  • Testosterone buciclate (20 Aet-1, CDB-1781) – a very long-acting testosterone ester that was under development but ultimately did not reach the market[4][5]

And the following less commonly known testosterone esters have also not been marketed:[1][2]

Dihydrotestosterone esters

[edit]

Marketed

[edit]

Several esters of dihydrotestosterone (DHT; androstanolone, stanolone) have also been marketed, including the following:[8][9]

Never marketed

[edit]

The following esters of DHT have not been marketed:[8][9]

Testifenon (chlorphenacyl DHT ester) is a nitrogen mustard ester of DHT that was developed as a cytostatic antineoplastic agent but was never marketed.[10]

Esters of other natural AAS

[edit]

Marketed

[edit]

The following esters of other natural AAS have been marketed:

Never marketed

[edit]

And the following have not been marketed:

Sturamustine is a nitrosourea ester of dehydroepiandrosterone (DHEA) that was developed as a cytostatic antineoplastic agent but was never marketed.[12][13]

Ethers of natural AAS

[edit]

Marketed

[edit]

Although not esters, the following ethers of natural AAS have been marketed as well:

Never marketed

[edit]

And the following have not been marketed:

Esters of synthetic AAS

[edit]

Methandriol esters

[edit]

Marketed

[edit]

Never marketed

[edit]

Nandrolone esters

[edit]

Marketed

[edit]

Many esters of the synthetic AAS nandrolone (19-nortestosterone) have been marketed, including the following major esters:[14][15][16]

And the following less commonly used esters:[14][15][16]

Never marketed

[edit]

The following nandrolone esters exist but were never marketed:

LS-1727 is a nitrosocarbamate ester of nandrolone that was developed as a cytostatic antineoplastic agent but was never marketed.[19]

Trenbolone esters

[edit]

Marketed

[edit]

A few esters of the synthetic AAS trenbolone have been marketed, including the following esters:

Never marketed

[edit]

The following trenbolone esters exist but were never marketed:

Esters of other synthetic AAS

[edit]

Marketed

[edit]

Many esters of other synthetic AAS have been marketed as well, including the following:

Never marketed

[edit]

Whereas the following have not been marketed:

Ethers of synthetic AAS

[edit]

Marketed

[edit]

Although not esters, the following ethers of synthetic AAS have been marketed as well:

Never marketed

[edit]

And the following have not been marketed:

See also

[edit]

References

[edit]
  1. 1 2 3 4 Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. ISBN 978-3-88763-075-1. Retrieved 29 May 2012.
  2. 1 2 3 4 5 6 7 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 642–. ISBN 978-1-4757-2085-3.
  3. William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 437–. ISBN 978-0-9828280-1-4.
  4. E. Nieschlag; H. M. Behre (1 April 2004). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 692–. ISBN 978-1-139-45221-2.
  5. Shalender Bhasin (13 February 1996). Pharmacology, Biology, and Clinical Applications of Androgens: Current Status and Future Prospects. John Wiley & Sons. pp. 471–. ISBN 978-0-471-13320-9.
  6. "R&D Research". www.evestra.com. Archived from the original on 2017-09-29.
  7. Ahmed G, Elger W, Meece F, Nair HB, Schneider B, Wyrwa R, Nickisch K (October 2017). "A prodrug design for improved oral absorption and reduced hepatic interaction". Bioorg. Med. Chem. 25 (20): 5569–5575. doi:10.1016/j.bmc.2017.08.027. PMID 28886996.
  8. 1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.
  9. 1 2 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
  10. Lagova ND, Sof'ina ZP, Shkodinskaia EN, Kurdiumova KN, Valueva IM (1988). "[The antineoplastic activity of testiphenon]". Vopr Onkol (in Russian). 34 (11): 1363–8. PMID 3201773.
  11. George W.A Milne (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 67–. ISBN 978-1-351-78989-9.
  12. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 1122. ISBN 978-1-4757-2085-3.
  13. Chavis C, de Gourcy C, Borgna JL, Imbach JL (1982). "New steroidal nitrosoureas". Steroids. 39 (2): 129–47. doi:10.1016/0039-128x(82)90081-2. PMID 7071885. S2CID 21042994.
  14. 1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 660–. ISBN 978-1-4757-2085-3.
  15. 1 2 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 716–717. ISBN 978-3-88763-075-1.
  16. 1 2 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. ISBN 978-94-011-4439-1.
  17. Lerner, Leonard J.; Holthaus, Fred J.; Thompson, Charles R. (1959). "A myotrophic agent and gonadotrophin inhibitor, 19-nortestosterone-17-benzoate". Endocrinology. 64 (6): 1010–1016. doi:10.1210/endo-64-6-1010. ISSN 0013-7227. PMID 13652918.
  18. Boschann, H. -W. (1955). "Cytologische Untersuchungen über die Wirkung von Androgenen am atrophischen Vaginalepithel in Abhängigkeit von Dosierung und Applikationsart". Archiv für Gynäkologie. 187 (1): 39–64. doi:10.1007/BF00985845. ISSN 0003-9128. PMID 13303168. S2CID 30443548.
  19. Hartley-Asp B, Wilkinson R, Venitt S, Harrap KR (1981). "Studies on the mechanism of action of LS 1727, a nitrosocarbamate of 19-nortestosterone". Acta Pharmacol Toxicol (Copenh). 48 (2): 129–38. doi:10.1111/j.1600-0773.1981.tb01598.x. PMID 6167141.